Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug…More
